ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 24.03
-1.12 (-4.45%)
At close: Jan 19, 2026
ANG Lifesciences India Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 922.09 | 928.47 | 1,461 | 2,199 | 3,543 | 1,544 | Upgrade |
Other Revenue | - | - | - | - | - | -0 | Upgrade |
| 922.09 | 928.47 | 1,461 | 2,199 | 3,543 | 1,544 | Upgrade | |
Revenue Growth (YoY) | -14.37% | -36.45% | -33.55% | -37.94% | 129.50% | 21.72% | Upgrade |
Cost of Revenue | 605.65 | 596.23 | 951.13 | 1,506 | 2,280 | 1,040 | Upgrade |
Gross Profit | 316.44 | 332.24 | 509.97 | 693.01 | 1,263 | 504.18 | Upgrade |
Selling, General & Admin | 176.53 | 178.11 | 196.85 | 243.32 | 214.77 | 139.98 | Upgrade |
Other Operating Expenses | 158.04 | 159.49 | 215.62 | 221.53 | 371.08 | 224.47 | Upgrade |
Operating Expenses | 398.92 | 405.2 | 496.19 | 558.38 | 644.6 | 377.62 | Upgrade |
Operating Income | -82.48 | -72.97 | 13.78 | 134.63 | 618.6 | 126.57 | Upgrade |
Interest Expense | -84.44 | -88.8 | -103.22 | -111.93 | -82.8 | -30.73 | Upgrade |
Interest & Investment Income | 2.26 | 2.26 | 5.28 | 6.46 | 2.9 | 2.03 | Upgrade |
Currency Exchange Gain (Loss) | - | - | -0.98 | -4.51 | -1.71 | - | Upgrade |
Other Non Operating Income (Expenses) | 2.47 | 2.47 | -6.35 | -6.85 | -0.93 | 3.53 | Upgrade |
EBT Excluding Unusual Items | -162.19 | -157.04 | -91.49 | 17.81 | 536.07 | 101.39 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 1.71 | 8.44 | -1.06 | - | Upgrade |
Other Unusual Items | - | - | -17.35 | - | - | - | Upgrade |
Pretax Income | -162.19 | -157.04 | -107.14 | 26.25 | 535.01 | 101.39 | Upgrade |
Income Tax Expense | -40.15 | -32.9 | -5.71 | 28.87 | 131.84 | 31.11 | Upgrade |
Net Income | -122.05 | -124.13 | -101.43 | -2.62 | 403.17 | 70.28 | Upgrade |
Net Income to Common | -122.05 | -124.13 | -101.43 | -2.62 | 403.17 | 70.28 | Upgrade |
Net Income Growth | - | - | - | - | 473.69% | 15.29% | Upgrade |
Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 13 | 13 | Upgrade |
Shares Outstanding (Diluted) | 13 | 13 | 13 | 13 | 13 | 13 | Upgrade |
Shares Change (YoY) | -0.45% | - | 0.51% | 0.26% | - | - | Upgrade |
EPS (Basic) | -9.39 | -9.51 | -7.77 | -0.20 | 31.11 | 5.42 | Upgrade |
EPS (Diluted) | -9.39 | -9.51 | -7.77 | -0.20 | 31.11 | 5.42 | Upgrade |
EPS Growth | - | - | - | - | 473.69% | 15.29% | Upgrade |
Free Cash Flow | 28.21 | -40.07 | -150.63 | 159.33 | -166.28 | 49 | Upgrade |
Free Cash Flow Per Share | 2.17 | -3.07 | -11.54 | 12.26 | -12.83 | 3.78 | Upgrade |
Dividend Per Share | - | - | - | - | 0.800 | - | Upgrade |
Gross Margin | 34.32% | 35.78% | 34.90% | 31.52% | 35.65% | 32.66% | Upgrade |
Operating Margin | -8.95% | -7.86% | 0.94% | 6.12% | 17.46% | 8.20% | Upgrade |
Profit Margin | -13.24% | -13.37% | -6.94% | -0.12% | 11.38% | 4.55% | Upgrade |
Free Cash Flow Margin | 3.06% | -4.32% | -10.31% | 7.25% | -4.69% | 3.17% | Upgrade |
EBITDA | -31.83 | -19.06 | 88.95 | 225.34 | 677.17 | 139.73 | Upgrade |
EBITDA Margin | -3.45% | -2.05% | 6.09% | 10.25% | 19.11% | 9.05% | Upgrade |
D&A For EBITDA | 50.66 | 53.91 | 75.17 | 90.71 | 58.58 | 13.17 | Upgrade |
EBIT | -82.48 | -72.97 | 13.78 | 134.63 | 618.6 | 126.57 | Upgrade |
EBIT Margin | -8.95% | -7.86% | 0.94% | 6.12% | 17.46% | 8.20% | Upgrade |
Effective Tax Rate | - | - | - | 109.99% | 24.64% | 30.69% | Upgrade |
Revenue as Reported | 928.07 | 948.66 | 1,468 | 2,296 | 3,552 | 1,549 | Upgrade |
Advertising Expenses | - | - | 0.08 | - | - | 0.73 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.